Corbus Pharmaceuticals (CRBP) 44th Annual J.P. Morgan Healthcare Conference summary

Oncology program milestones and data updates

• CRB-701 shows promising activity in second-line head and neck and cervical cancer, with maturing durability data expected later this year.

• Ongoing FDA discussions this quarter will clarify registrational pathways for both second-line head and neck and cervical indications.

• Front-line head and neck study with Keytruda is underway, with initial data expected to mature by year-end.

• CRB-701 features a proprietary MAB with higher internalization and a stable linker, resulting in lower circulating MMAE and fewer adverse events compared to Padcev.

• Safety profiles in US/European and Chinese populations are similar, with low peripheral neuropathy and skin toxicity.

Obesity program insights and clinical data

• CRB-913, a peripherally restricted CB1 inverse agonist, demonstrated robust weight loss and a favorable safety profile in early studies.

• No neuropsychiatric adverse events were observed, even at high doses, differentiating it from monlunabant and first-generation drugs.

• Participants reported appetite suppression and reduced food cravings, with weight loss starting early and deepening over time.

• CRB-913 showed greater potency than rimonabant and orforglipron in short-term comparisons, with minimal GI side effects.

• Upcoming phase 1B study will use titration and provide granular safety and dose-response data by late summer 2026.

Strategic positioning and financial outlook

• CRB-913 could serve as maintenance therapy post-incretin analogs, an alternative for intolerant or non-responsive patients, or as a combination therapy.

• Cash position of $172 million provides operational runway into 2028 for both oncology and obesity programs.